Clinical Trials Directory

Trials / Completed

CompletedNCT02690025

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Zealand Pharma · Industry
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.

Conditions

Interventions

TypeNameDescription
DRUGZP1848

Timeline

Start date
2016-02-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2016-02-24
Last updated
2017-06-21

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02690025. Inclusion in this directory is not an endorsement.

A Phase 2 Trial Testing ZP1848 in Patients With SBS (NCT02690025) · Clinical Trials Directory